Round cell liposarcoma is a rare and aggressive form of cancer that develops in fat tissue, most commonly in the arms and legs. This condition represents a more serious variant within the myxoid liposarcoma family, requiring specialized care and a multidisciplinary approach to treatment. Understanding the options available—from surgery and radiation to cutting-edge therapies being tested in clinical trials—can help patients and families navigate this challenging diagnosis with greater confidence.

Pathways to Managing a Rare Cancer

When someone receives a diagnosis of round cell liposarcoma, the first step is understanding what this means for their treatment journey. The primary goal of therapy is to remove the tumor completely and prevent it from spreading to other parts of the body. Because this cancer tends to grow more aggressively than other types of liposarcoma, treatment often involves multiple approaches working together. Doctors consider several factors when planning care, including the tumor’s size, location, whether it has spread, and the patient’s overall health.^[1]

Round cell liposarcoma typically affects people between the ages of 20 and 40, which is younger than most other liposarcomas. The condition accounts for approximately 30% of all liposarcoma cases in the United States, with about 2,000 people diagnosed with liposarcoma each year across all types.^[1] The tumor usually appears as a painless lump under the skin, most often in the thigh, though it can develop in other areas of the arms or legs.^[2]

Treatment planning begins with a team of specialists, including surgeons, oncologists (doctors who specialize in cancer treatment), and radiation oncologists (doctors who use radiation to treat cancer). This team approach ensures that every aspect of the disease is addressed. Patients benefit from seeking care at centers with experience treating rare sarcomas, as these facilities have the expertise needed to manage complex cases.^[1]

Standard Treatment Approaches

Surgery remains the cornerstone of treatment for round cell liposarcoma. The surgeon’s goal is to remove the entire tumor along with a surrounding border of healthy tissue, called a margin. This margin helps ensure that any cancer cells invisible to the naked eye are removed along with the tumor, which reduces the chance of the cancer coming back in the same location.^[1] The surgery is often complex because the tumor may be near important nerves, blood vessels, or muscles.

Before surgery, patients undergo detailed imaging tests, including computed tomography (CT) scans and magnetic resonance imaging (MRI) scans. CT scans use X-rays to create detailed cross-sectional images of the body, helping doctors see the tumor’s exact location and size. MRI scans use magnetic fields and radio waves to produce detailed pictures of soft tissues, allowing doctors to assess how the tumor relates to nearby nerves, blood vessels, and muscles.^[1] These images guide surgical planning and help the team determine whether additional treatments will be needed.

After imaging, a biopsy is performed to confirm the diagnosis. During a biopsy, a doctor removes a small sample of tissue from the tumor using a needle. An expert called a pathologist then examines the cells under a microscope to determine the exact type of liposarcoma. In round cell liposarcoma, the pathologist looks for the presence of round-shaped cells, which distinguish this aggressive form from the slower-growing myxoid type.^[1] The amount of round cells present—with more than 5% being significant—helps predict how the tumor might behave and guides treatment decisions.^[6]

Radiation Therapy in Standard Care

Radiation therapy plays an important role in treating round cell liposarcoma and can be used at different times during treatment. Radiation therapy uses high-energy beams to destroy cancer cells. When given before surgery, it aims to shrink the tumor, making it easier to remove completely. This approach, called neoadjuvant therapy, can also reduce the amount of healthy tissue that needs to be removed during surgery.^[1]

Radiation can also be given after surgery if the surgeon is concerned that some tumor cells may remain, or if the margin around the removed tumor was close to cancer cells. This adjuvant therapy approach helps prevent the cancer from returning in the same location. Round cell liposarcoma responds particularly well to radiation compared to many other types of sarcoma, making this treatment especially valuable.^[6] Radiation therapy is typically delivered over several weeks, with small doses given each day to minimize side effects while maximizing cancer-killing effects.

Side effects from radiation therapy depend on the area being treated and the dose given. Common side effects include fatigue, skin changes in the treatment area that resemble sunburn, and temporary swelling. Most of these effects are temporary and resolve after treatment ends, though some patients may experience long-term changes in the treated area, such as skin texture changes or reduced flexibility.

Chemotherapy as Part of Standard Treatment

Chemotherapy uses medications to kill cancer cells throughout the body. For round cell liposarcoma, chemotherapy is typically considered when the tumor is large (greater than 5 centimeters), difficult to remove completely with surgery, or has already spread to other parts of the body.^[1] Unlike surgery and radiation, which target the tumor in one location, chemotherapy travels through the bloodstream to reach cancer cells anywhere in the body.

The most commonly used chemotherapy drugs for liposarcoma include doxorubicin and ifosfamide. Doxorubicin belongs to a class of drugs called anthracyclines, which work by interfering with the DNA inside cancer cells, preventing them from dividing and growing. Ifosfamide is an alkylating agent that damages the DNA of cancer cells in a different way. These drugs are often used together because they attack cancer cells through different mechanisms, making the treatment more effective.^[6]

Round cell liposarcoma tends to be more sensitive to chemotherapy than other types of liposarcoma, meaning the cancer cells are more likely to respond to these medications. However, chemotherapy still affects normal cells along with cancer cells, leading to side effects. Common side effects include nausea, hair loss, fatigue, increased risk of infection due to lowered white blood cell counts, and sometimes heart problems with certain drugs. Patients receiving chemotherapy are closely monitored, and medications can be given to help manage side effects.

A second-line chemotherapy option is trabectedin (brand name Yondelis), which was approved in the United States in 2015 for patients whose cancer has spread or cannot be removed by surgery, and who have already tried anthracycline-based chemotherapy. Trabectedin works differently from traditional chemotherapy—it binds to specific parts of the DNA inside cells, interfering with cell division and triggering cancer cell death. Clinical trials showed that trabectedin improved the time patients lived without their cancer worsening, though it did not improve overall survival.^[15]

Another medication, eribulin (brand name Halaven), was approved by the FDA in 2016 for similar situations. Eribulin is a microtubule inhibitor, meaning it prevents cancer cells from dividing properly by interfering with structures inside cells called microtubules. In patients with liposarcoma who had previously received anthracycline-based treatment, eribulin showed a 7-month improvement in survival compared to the chemotherapy drug dacarbazine (15.6 months versus 8.4 months).^[15] However, eribulin also causes more side effects than some other chemotherapy drugs, including low white blood cell counts, fever, nerve damage causing numbness or tingling in the hands and feet, and hair loss.

Treatment in Clinical Trials

Beyond standard treatments, researchers are constantly studying new approaches to treat round cell liposarcoma. Clinical trials are carefully designed research studies that test new treatments to see if they are safe and effective. Participating in a clinical trial may give patients access to promising new therapies before they become widely available. Clinical trials proceed through phases, each with a specific purpose.

Understanding Clinical Trial Phases

Phase I trials are the first step in testing a new treatment in humans. These studies focus primarily on safety—determining the right dose, identifying side effects, and understanding how the body processes the new medication. Phase I trials typically involve a small number of patients and are often offered to people whose cancer has not responded to standard treatments.

Phase II trials continue safety monitoring but focus more on whether the treatment actually works against the cancer. Researchers measure how many patients’ tumors shrink, how long the benefit lasts, and which types of cancer respond best. Phase II trials involve more patients than Phase I studies and provide important information about whether a treatment is worth studying further.

Phase III trials compare the new treatment directly to the current standard treatment. These large studies may involve hundreds or even thousands of patients and aim to prove whether the new treatment is better than, equal to, or worse than existing options. Successful Phase III trials often lead to new treatments being approved for widespread use.

Targeted Therapies Under Investigation

Round cell liposarcoma has a distinctive genetic feature that makes it an attractive target for new therapies. In most cases, a piece of a chromosome (the structure in cells that carries genes) breaks off and attaches to another chromosome in the wrong place. This error causes two genes, FUS and CHOP (also called DDIT3), to join together inappropriately. The resulting abnormal protein, called a fusion protein, disrupts normal cell processes and prevents fat cells from maturing properly, contributing to cancer development.^[1] This happens in almost all cases of round cell liposarcoma, making it a distinctive marker of the disease.^[6]

Researchers are working to develop drugs that specifically target this FUS-CHOP fusion protein or the pathways it disrupts. These targeted therapies aim to attack cancer cells while causing less harm to normal cells than traditional chemotherapy. While specific drug names and trial results for agents targeting FUS-CHOP are still emerging, the concept represents an important direction in sarcoma research.

Scientists are also investigating ways to use the body’s own immune system to fight cancer. Immunotherapy treatments help the immune system recognize and destroy cancer cells. Some approaches use antibodies designed to bind to specific proteins on cancer cells, marking them for destruction. Others work by removing the “brakes” on immune cells, allowing them to attack cancer more effectively. Various immunotherapy strategies are being tested in clinical trials for sarcomas, including round cell liposarcoma.

Innovative Treatment Approaches

One area of active research involves medications that interfere with how cancer cells divide and grow by targeting specific molecules. Enzyme inhibitors block proteins that cancer cells need to survive and multiply. By understanding the specific molecular pathways that drive round cell liposarcoma, researchers can design drugs that interrupt these processes.

Another promising area is combination therapy research, which tests whether using multiple treatments together works better than using them alone. For example, clinical trials may combine standard chemotherapy with newer targeted drugs, or test whether adding immunotherapy to standard treatment improves outcomes. The goal is to find combinations that are more effective while keeping side effects manageable.

Clinical trials for round cell liposarcoma are conducted at specialized sarcoma centers in the United States, Europe, and other regions worldwide. Patients interested in participating should discuss options with their oncology team. Eligibility for trials depends on many factors, including the stage of disease, previous treatments received, overall health status, and specific characteristics of the tumor. Not everyone will qualify for every trial, but the oncology team can help identify appropriate options.

Most common treatment methods

• Surgery
  • Wide excision of the tumor along with surrounding healthy tissue to ensure complete removal
  • Limb-sparing procedures that preserve function while removing the cancer
  • Amputation in rare cases when the tumor cannot be safely removed while preserving the limb
• Radiation Therapy
  • Preoperative (neoadjuvant) radiation to shrink tumors before surgical removal
  • Postoperative (adjuvant) radiation to eliminate remaining cancer cells and prevent recurrence
  • Particularly effective in round cell liposarcoma compared to other sarcoma types
• Chemotherapy
  • Doxorubicin and ifosfamide as first-line treatment options for advanced or unresectable tumors
  • Trabectedin (Yondelis) as second-line therapy for patients who have received anthracycline-based treatment
  • Eribulin (Halaven) for patients with liposarcoma that has spread, showing improved survival in clinical trials
  • More effective in round cell liposarcoma than in other liposarcoma subtypes

Long-term Follow-up and Prognosis

After completing treatment, patients require regular follow-up care to monitor for any signs that the cancer has returned. The term prognosis refers to the likely course and outcome of the disease. For round cell liposarcoma, prognosis depends on several factors, including where the tumor is located in the body, whether it has spread to other areas, how much of the tumor was removed during surgery, and the percentage of round cells present in the tumor.^[1]

The five-year survival rate for patients with small round cell liposarcoma that has not spread is over 80%, meaning that more than 8 out of 10 patients are still alive five years after diagnosis.^[1] However, tumors with a high percentage of round cells tend to have a poorer prognosis than those with primarily myxoid cells. About one-third of patients with myxoid/round cell liposarcoma will develop metastases, meaning the cancer spreads to other parts of the body.^[6]

Round cell liposarcoma has unusual spreading patterns compared to other cancers. While many cancers spread first to nearby lymph nodes, this tumor more often spreads to unusual locations, including bones (such as the pelvis or spine), other soft tissue areas, and organs like the heart, lungs, or the space around the heart (pericardium). It can also appear in multiple locations at once or develop new tumors over time in different fat-containing areas of the body.^[2]

Follow-up schedules are personalized but typically include regular physical examinations, imaging studies to check for recurrence, and chest X-rays to monitor for lung metastases. Patients should receive a specific follow-up plan from their sarcoma clinical nurse specialist. Lifelong follow-up is recommended because recurrence can occur years after initial treatment.^[6] If cancer does return, catching it early provides the best opportunity for successful treatment.